Bainan Biotech


About Bainan Biotech



Bainan Biotech is a spinout company which is founded on years of research exploring the connection between gut hormones and bone turnover, carried out at the University of Copenhagen. We aim to utilise the natural responses to eating in order to promote the formation of stronger and healthier bone tissue and develop effective treatments for osteoporosis. Specifically, we are adapting our product to be effective in premenopausal women, a patient group which currently is vastly under-served in this area.


Our Target Patients


Premenopausal Osteoporosis

Osteoporosis is a condition of deteriorating bone mineralisation, resulting in increased risk of fractures. It is silently progressing over time posing a need to stop the disease process and prevent the weakening of the bones. Secondary osteoporosis, in particular among pre-menopausal women, is insufficiently treated as the widely used drugs for post-menopausal osteoporosis cannot be used due to teratogenicity, carcinogenicity, strong rebound effects, or lack of efficacy in this group.



Our Science

bone fysiology.png

GLP-2/GIP and Bone Metabolism

Bone remodeling is a process of bone formation and bone resorption. Bone turnover has a marked circadian variation, with higher bone resorption during night time and a correspondingly lower resorption during the day time.The mechanism regulating this rhythm seems to be related to food intake. The founders and others have shown that gut hormones are involved, that GLP-2 inhibits bone resorption, and that treating humans with GLP-2 results in increased bone mineral density. Furthermore, that GIP also affects bone metabolism in man.

The Bainan Approach

Created upon a thorough analysis of receptor ligand interactions for the GIP and the GLP-2 system, structural information of receptors and peptide hormones, Bainan Biotech has successfully created a series of dual-agonists with nano-molar potency. These have succesfully been modified to prolong their half-life and cross-checked for selectivity against other class B1 (secretin-like) receptors.